Insulet Pre-Tax Profit Margin 2010-2024 | PODD
Current and historical pre-tax profit margin for Insulet (PODD) from 2010 to 2024. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue. Insulet pre-tax profit margin for the three months ending September 30, 2024 was .
| Insulet Pre-Tax Profit Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Pre-Tax Income | Pre-Tax Margin |
| 2024-09-30 | $1.99B | $0.30B | 14.96% |
| 2024-06-30 | $1.87B | $0.27B | 14.30% |
| 2024-03-31 | $1.78B | $0.25B | 13.80% |
| 2023-12-31 | $1.70B | $0.22B | 12.72% |
| 2023-09-30 | $1.56B | $0.13B | 8.34% |
| 2023-06-30 | $1.47B | $0.07B | 4.77% |
| 2023-03-31 | $1.37B | $0.01B | 0.37% |
| 2022-12-31 | $1.31B | $0.01B | 0.69% |
| 2022-09-30 | $1.24B | $0.02B | 1.61% |
| 2022-06-30 | $1.18B | $0.04B | 3.48% |
| 2022-03-31 | $1.14B | $0.05B | 4.29% |
| 2021-12-31 | $1.10B | $0.02B | 1.82% |
| 2021-09-30 | $1.04B | $-0.03B | -3.09% |
| 2021-06-30 | $1.00B | $-0.03B | -3.42% |
| 2021-03-31 | $0.96B | $0.01B | 1.15% |
| 2020-12-31 | $0.90B | $0.01B | 0.88% |
| 2020-09-30 | $0.87B | $0.03B | 3.92% |
| 2020-06-30 | $0.83B | $0.02B | 2.67% |
| 2020-03-31 | $0.78B | $0.01B | 0.90% |
| 2019-12-31 | $0.74B | $0.02B | 2.03% |
| 2019-09-30 | $0.69B | $0.02B | 2.74% |
| 2019-06-30 | $0.65B | $0.02B | 3.06% |
| 2019-03-31 | $0.60B | $0.02B | 2.83% |
| 2018-12-31 | $0.56B | $0.01B | 1.06% |
| 2018-09-30 | $0.53B | $-0.01B | -2.26% |
| 2018-06-30 | $0.50B | $-0.02B | -3.19% |
| 2018-03-31 | $0.49B | $-0.02B | -4.72% |
| 2017-12-31 | $0.47B | $-0.03B | -5.81% |
| 2017-09-30 | $0.44B | $-0.03B | -6.62% |
| 2017-06-30 | $0.41B | $-0.03B | -7.30% |
| 2017-03-31 | $0.39B | $-0.03B | -6.70% |
| 2016-12-31 | $0.37B | $-0.03B | -7.36% |
| 2016-09-30 | $0.35B | $-0.03B | -9.80% |
| 2016-06-30 | $0.32B | $-0.05B | -15.17% |
| 2016-03-31 | $0.30B | $-0.06B | -20.88% |
| 2015-12-31 | $0.26B | $-0.06B | -23.11% |
| 2015-09-30 | $0.20B | $-0.05B | -24.10% |
| 2015-06-30 | $0.20B | $-0.04B | -20.10% |
| 2015-03-31 | $0.21B | $-0.05B | -24.76% |
| 2014-12-31 | $0.23B | $-0.05B | -20.78% |
| 2014-09-30 | $0.29B | $-0.05B | -17.19% |
| 2014-06-30 | $0.27B | $-0.06B | -21.77% |
| 2014-03-31 | $0.26B | $-0.04B | -15.44% |
| 2013-12-31 | $0.25B | $-0.05B | -18.22% |
| 2013-09-30 | $0.24B | $-0.05B | -22.03% |
| 2013-06-30 | $0.23B | $-0.04B | -18.70% |
| 2013-03-31 | $0.22B | $-0.05B | -21.27% |
| 2012-12-31 | $0.21B | $-0.05B | -24.06% |
| 2012-09-30 | $0.20B | $-0.06B | -27.36% |
| 2012-06-30 | $0.19B | $-0.06B | -29.84% |
| 2012-03-31 | $0.17B | $-0.06B | -36.05% |
| 2011-12-31 | $0.15B | $-0.06B | -37.50% |
| 2011-09-30 | $0.13B | $-0.06B | -48.12% |
| 2011-06-30 | $0.11B | $-0.06B | -54.87% |
| 2011-03-31 | $0.10B | $-0.06B | -54.81% |
| 2010-12-31 | $0.10B | $-0.06B | -62.89% |
| 2010-09-30 | $0.09B | $-0.06B | -62.92% |
| 2010-06-30 | $0.08B | $-0.06B | -73.49% |
| 2010-03-31 | $0.08B | $-0.07B | -89.33% |
| 2009-12-31 | $0.07B | $-0.07B | -110.61% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $18.443B | $1.697B |
| Insulet Corporation is a leading developer, manufacturer and marketer of the Omnipod Insulin Management System. The system is equipped with a self-adhesive, small and lightweight disposable tubeless Omnipod device along with the wireless and handheld Personal Diabetes Manager (PDM). The Omnipod System is an innovative, discreet and easy-to-use continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System consists of Omnipod Insulin Management System ('Omnipod') and the Omnipod DASH Insulin Management System - Insulet's next generation digital mobile Omnipod platform. Insulet has tied up with pharmaceutical and biotechnological companies using customized form of the Omnipod System to deliver a drug at a certain administered volume and over a specified period of time. Insulet has partnered with pharmaceutical and biotechnology companies to tailor the Omnipod System technology platform for the delivery of subcutaneous drugs across other therapeutic areas. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $204.249B | 26.05 |
| Stryker (SYK) | United States | $146.711B | 33.06 |
| Boston Scientific (BSX) | United States | $132.644B | 38.14 |
| EssilorLuxottica (ESLOY) | France | $112.106B | 0.00 |
| Medtronic (MDT) | Ireland | $110.562B | 16.42 |
| Haleon (HLN) | United Kingdom | $43.682B | 28.38 |
| Lonza Group Ag (LZAGY) | Switzerland | $42.166B | 0.00 |
| GE HealthCare Technologies (GEHC) | United States | $37.665B | 19.54 |
| ResMed (RMD) | United States | $35.786B | 29.41 |
| Terumo (TRUMY) | Japan | $29.739B | 0.00 |
| Koninklijke Philips (PHG) | Netherlands | $24.805B | 18.99 |
| Zimmer Biomet Holdings (ZBH) | United States | $21.942B | 13.97 |
| Baxter (BAX) | United States | $16.957B | 11.03 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $11.065B | 0.00 |
| BellRing Brands (BRBR) | United States | $10.158B | 40.72 |
| Bio-Rad Laboratories (BIO) | United States | $9.320B | 31.68 |
| Demant (WILYY) | Denmark | $8.342B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $6.294B | 14.62 |
| TG Therapeutics (TGTX) | United States | $5.459B | 0.00 |
| Haemonetics (HAE) | United States | $4.297B | 20.97 |
| Prestige Consumer Healthcare (PBH) | United States | $4.192B | 20.85 |
| ICU Medical (ICUI) | United States | $4.125B | 39.27 |
| Perrigo (PRGO) | Ireland | $3.830B | 11.27 |
| Envista Holdings (NVST) | United States | $3.697B | 27.54 |
| Neogen (NEOG) | United States | $3.246B | 37.45 |
| Agios Pharmaceuticals (AGIO) | United States | $3.175B | 0.00 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.010B | 0.00 |
| GN Store Nord (GNNDY) | Denmark | $2.841B | 18.22 |
| QuidelOrtho (QDEL) | United States | $2.700B | 17.38 |
| LeMaitre Vascular (LMAT) | United States | $2.428B | 59.00 |
| Warby Parker (WRBY) | United States | $2.349B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.913B | 33.48 |
| AtriCure (ATRC) | United States | $1.742B | 0.00 |
| InMode (INMD) | Israel | $1.597B | 9.61 |
| AdaptHealth (AHCO) | United States | $1.326B | 9.48 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.318B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $1.267B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.207B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.962B | 16.96 |
| Owens & Minor (OMI) | United States | $0.952B | 7.44 |
| CeriBell (CBLL) | United States | $0.943B | 0.00 |
| National Vision Holdings (EYE) | United States | $0.918B | 30.68 |
| Capricor Therapeutics (CAPR) | United States | $0.847B | 0.00 |
| Evolus (EOLS) | United States | $0.798B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.684B | 30.25 |
| Omeros (OMER) | United States | $0.632B | 0.00 |
| Surmodics (SRDX) | United States | $0.563B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.533B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.522B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.468B | 0.00 |
| Quanterix (QTRX) | United States | $0.451B | 0.00 |
| ZimVie (ZIMV) | United States | $0.391B | 32.95 |
| Valneva SE (VALN) | France | $0.360B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.341B | 32.41 |
| Cerus (CERS) | United States | $0.332B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.330B | 0.00 |
| Biote (BTMD) | United States | $0.325B | 7.12 |
| OraSure Technologies (OSUR) | United States | $0.289B | 19.40 |
| Zynex (ZYXI) | United States | $0.263B | 55.07 |
| Aurora Cannabis (ACB) | Canada | $0.238B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.225B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.221B | 15.29 |
| High Tide (HITI) | Canada | $0.213B | 88.33 |
| MacroGenics (MGNX) | United States | $0.203B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.188B | 2.64 |
| Brainsway (BWAY) | Israel | $0.167B | 100.00 |
| Organigram Holdings (OGI) | Canada | $0.166B | 0.00 |
| Jin Medical (ZJYL) | China | $0.164B | 0.00 |
| Zevia PBC (ZVIA) | United States | $0.160B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.149B | 18.67 |
| TriSalus Life Sciences (TLSI) | United States | $0.138B | 0.00 |
| Fonar (FONR) | United States | $0.104B | 11.74 |
| Quipt Home Medical (QIPT) | United States | $0.104B | 0.00 |
| Veru (VERU) | United States | $0.099B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.094B | 23.40 |
| Ayr Wellness (AYRWF) | United States | $0.077B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.073B | 37.50 |
| Exagen (XGN) | United States | $0.072B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.065B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.063B | 0.00 |
| InterCure (INCR) | Israel | $0.062B | 0.00 |
| Modular Medical (MODD) | United States | $0.058B | 0.00 |
| MariMed (MRMD) | United States | $0.057B | 0.00 |
| Apyx Medical (APYX) | United States | $0.054B | 0.00 |
| Safety Shot (SHOT) | United States | $0.051B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.050B | 0.00 |
| ImmuCell (ICCC) | United States | $0.033B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.028B | 0.00 |
| Flora Growth (FLGC) | United States | $0.019B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.018B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.016B | 0.00 |
| Nephros (NEPH) | United States | $0.016B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.009B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.009B | 0.00 |
| Sharps Technology (STSS) | United States | $0.006B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.006B | 0.00 |
| Agape ATP (ATPC) | $0.006B | 0.00 | |
| Leafly Holdings (LFLY) | United States | $0.005B | 0.00 |
| Senestech (SNES) | United States | $0.002B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.002B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.001B | 0.00 |
| United-Guardian (UG) | United States | $0.000B | 12.83 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |